Bohuslav Karlík

Recent publications · Crossref

5 total works indexed

1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

   · 2018 · cited 3,966x

2. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

   · 2019 · cited 2,930x

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

   · 2019 · cited 2,827x

4. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

   · 2007 · cited 1,828x

5. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

   · 2014 · cited 1,796x

via Crossref · CC0

Wikidata facts